Floatz Rating
C37/100
Confidence
Indicative
Sponsor
UNC Lineberger Comprehensive Cancer Center
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03602157CT.gov Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atlcar.Cd30.Ccr4 Cells (this asset) | UNC Lineberger Comprehensive Cancer Center | P1 | C · 37 |
| Panitumumab | Astellas Pharma Inc | P2 | BB |
| Irinotecan | Mirati Therapeutics Inc. | P4 | BB |
| Nivestim | Ankara Etlik City Hospital | P2 | BB |
| Dexasone | Hellenic Society of Hematology | P3 | BB |
| Feladilimab | GlaxoSmithKline | P2 | BB |
| Carboplatin | Bristol-Myers Squibb | P3 | BB |
| Pralsetinib, Trans- | Seoul National University Bundang Hospital | P3 | BB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Atlcar.Cd30.Ccr4 Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Immune System Disorder | — | P1 | CC · 43 |
| Immunoproliferative Disorder | — | P1 | CC · 43 |
| Lymphatic System Disorder | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Atlcar.Cd30.Ccr4 Cells in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/atlcarcd30ccr4-cells-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →